Skip to main content
. Author manuscript; available in PMC: 2010 Oct 1.
Published in final edited form as: Br J Haematol. 2009 Oct;147(2):246–261. doi: 10.1111/j.1365-2141.2009.07828.x

Figure 3.

Figure 3

(A) Estimated progression-free survival according to histological subtype. Patients with indolent non-Hodgkin lymphoma (NHL: yellow line), mantle-cell lymphoma (blue line), aggressive NHL (grey line), and Hodgkin lymphoma (red line). (B) Estimated progression-free survival according to the use of total-body irradiation (TBI). Patients who received low-dose TBI-containing regimens (yellow line), high-dose TBI (blue line), or no TBI (gray line) after umbilical cord blood transplantation for lymphoid malignancies.

From Rodrigues, C et al J Clin Oncol, 27, (2009) 256-263. Reprinted with permission. © 2009 American Society of Clinical Oncology. All rights reserved.